Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding
Language English Country Sweden Media print
Document type Journal Article
PubMed
39688660
PII: 45052405
Knihovny.cz E-resources
- MeSH
- Antithrombins adverse effects therapeutic use MeSH
- Dabigatran * adverse effects MeSH
- Adult MeSH
- Pharmacogenetics MeSH
- Gastrointestinal Hemorrhage * genetics chemically induced MeSH
- Genotype MeSH
- Factor Xa Inhibitors adverse effects therapeutic use MeSH
- Polymorphism, Single Nucleotide * MeSH
- Middle Aged MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Pyrazoles * adverse effects therapeutic use MeSH
- Pyridones * adverse effects therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- ABCB1 protein, human MeSH Browser
- Antithrombins MeSH
- apixaban MeSH Browser
- Dabigatran * MeSH
- Factor Xa Inhibitors MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Pyrazoles * MeSH
- Pyridones * MeSH
OBJECTIVES: To determine whether selected single nucleotide polymorphisms (SNPs) of genes encoding proteins responsible for the activation, transport, or metabolism of dabigatran and apixaban might be associated with a risk of gastrointestinal bleeding in a cohort of adult patients treated with these drugs. No previous study has focused specifically on the association with gastrointestinal bleeding. MATERIALS AND METHODS: Ninety-one patients treated with dabigatran or apixaban were genotyped for selected polymorphisms. The following polymorphisms were studied: ABCB1 gene rs1045642, rs4148738, rs1128503 and rs2032582; CES1 gene rs2244613, rs8192935 and rs2244614; and SULT1A1 gene rs9282861 and SULT1A2 gene rs1136703. Two groups divided by particular drugs and genotypes were compared in terms of the presence (bleeding group) or absence (nonbleeding group) of gastrointestinal bleeding. The genotype distribution was expressed via dominant and recessive models. RESULTS: In patients treated either with dabigatran or with apixaban, no evidence was found to support the association of gastrointestinal bleeding with any genotype for any of the studied SNPs. CONCLUSION: In both dabigatran- and apixaban-treated patients, no associations between the selected polymorphisms and gastrointestinal bleeding risk were found, however the results should be interpreted with caution because of the small cohort size.
